Results 91 to 100 of about 16,465 (200)

TABLE 3 from Analysis of Changes in Plasma Cytokine Levels in Response to IL12 Therapy in Three Clinical Trials

Statistical analysis of cytokine profile changes after IL12 treatment within patient response groups. Cytokine profiles consisting of 23 different cytokines were analyzed for significant changes between baseline and 72 hours post-IL12 therapy within ...
Emily Schwarz (15054365), William E. Carson (15054380), Brooke Benner (15054338), Fode Tounkara (17767997), Lianbo Yu (8863337)   +4 more
core   +1 more source

IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis.

PLoS ONE, 2019
Leishmania infantum causes zoonotic visceral leishmaniasis (ZVL) in the Mediterranean basin and South America. The parasite has been shown to co-infect HIV patients and an outbreak in central Spain was reported in the last decade.
Pedro J Alcolea, Ana Alonso, Adriana Esteban, Paz Peris, Alberto Cortés, Juan A Castillo, Vicente Larraga   +6 more
doaj   +1 more source

Subcutaneous administration of NHS-IL12 resulted in measurable serum drug levels.

, 2015
Serum samples were collected from dogs to define systemic exposures of NHS-IL12 after subcutaneous administration. NHS-IL12 levels were measured pre-treatment and at 1, 2, 4, 8, 24, 36, and 48 hours following administration (8-point collection) and on ...
Matti Kiupel (16621), Beatrice Brunkhorst (757924), Heather Wilson (519870), David Vail (373607), Christina Mazcko (247733), Katherine Skorupski (757920), Amy LeBlanc (373605), Susan Lana (247736), Lisa Barber (688335), Anne Avery (757922), Robert Tighe (757925), Kimberly Selting (757918), Melissa Paoloni (219264), Barbara Biller (757921), Anna Bernhardt (757923), Chand Khanna (219274), Jeffrey Phillips (757919)   +16 more
core   +1 more source

Supplementary Fig. S.4 from NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

, 2017
Intra-tumoral vaccination is essential to maximize the benefit of MG1-IL12-ICV vaccine.
Abhirami A. Ananth (2794732), Andrew P. Makrigiannis (14911220), E. Celia Marginean (15115049), Jiqing Zhang (419946), Michael A. Kennedy (230327), Shalini Sahi (14991576), Greg O. Cron (9936684), Blair Macdonald (15115046), Charles Lefebvre (15114515), Almohanad A. Alkayyal (2794729), Christiano Tanese de Souza (2794726), Ahmad Bakur Mahmoud (13946295), David F. Stojdl (14049867), Rebecca C. Auer (2794744), John C. Bell (206340), Lee-Hwa Tai (2794741)   +15 more
core   +1 more source

Supplementary Fig. S.7 from NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

, 2017
MG1-IL12-ICV vaccine enhances natural killer cell recruitment and function via dendritic cells.
Abhirami A. Ananth (2794732), Andrew P. Makrigiannis (14911220), E. Celia Marginean (15115049), Jiqing Zhang (419946), Michael A. Kennedy (230327), Shalini Sahi (14991576), Greg O. Cron (9936684), Blair Macdonald (15115046), Charles Lefebvre (15114515), Almohanad A. Alkayyal (2794729), Christiano Tanese de Souza (2794726), Ahmad Bakur Mahmoud (13946295), David F. Stojdl (14049867), Rebecca C. Auer (2794744), John C. Bell (206340), Lee-Hwa Tai (2794741)   +15 more
core   +1 more source

The role of IL12 in toxoplasmosis

Research in Immunology, 1995
C A, Hunter, J S, Remington
openaire   +2 more sources

Intraperitoneal administration of mRNA encoding interleukin-12 for immunotherapy in peritoneal carcinomatosis

Journal of Nanobiotechnology
Peritoneal carcinomatosis is an advanced stage of cancer with very limited treatment options. Locoregional immunotherapy is being evaluated as a way to improve efficacy and limit toxicity.
Leire Arrizabalaga, Claudia Augusta Di Trani, Myriam Fernández-Sendin, Ángela Bella, Joan Salvador Russo-Cabrera, Celia Gomar, Nuria Ardaiz, Virginia Belsue, José González-Gomariz, Sara Zalba, Adrián Gil-Korilis, Maria J. Garrido, Ignacio Melero, Fernando Aranda, Pedro Berraondo   +14 more
doaj   +1 more source

Study schedule for dose escalation and cohort expansion of NHS-IL12 administered subcutaneously.

, 2015
CBC: complete blood count; IFN, interferon; PBMC, peripheral blood mononuclear cell; Tx: treatment; UA: urinalysis.Study schedule for dose escalation and cohort expansion of NHS-IL12 administered subcutaneously.
Matti Kiupel (16621), Beatrice Brunkhorst (757924), Heather Wilson (519870), David Vail (373607), Christina Mazcko (247733), Katherine Skorupski (757920), Amy LeBlanc (373605), Susan Lana (247736), Lisa Barber (688335), Anne Avery (757922), Robert Tighe (757925), Kimberly Selting (757918), Melissa Paoloni (219264), Barbara Biller (757921), Anna Bernhardt (757923), Chand Khanna (219274), Jeffrey Phillips (757919)   +16 more
core   +1 more source

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

, 2017
Despite improvements in chemotherapy and radical surgical debulking, peritoneal carcinomatosis (PC) remains among the most common causes of death from abdominal cancers.
Almohanad A. Alkayyal, Andrew P. Makrigiannis, Lee-Hwa Tai, Michael A. Kennedy, Christiano Tanese de Souza, Ahmad Bakur Mahmoud, E. Celia Marginean, Blair Macdonald, John C. Bell, Greg O. Cron, Abhirami A. Ananth, David F. Stojdl, Rebecca C. Auer, Shalini Sahi, Jiqing Zhang, Charles Lefebvre   +15 more
core   +1 more source

Figure 3. Antigen-specific binding of antibody targeted IL-2 and IL12 fusion proteins.

, 2013
(A) Equimolar amounts of the scFv-Fc fusion proteins were incubated in serial dilutions in micro-titer plates coated with the anti-idiotypic mAb 9G10 which binds to the HRS3 scFv antibody targeting domain of the fusion proteins. For control, same amounts
Stefan Guhlke (307234), Andreas A. Hombach (169001), Claudia Heuser (307231), Björn Friedrichs (307229), Hinrich Abken (107201), Tobias Jahn (307225), Martin Zuther (307227)   +6 more
core   +1 more source